Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00221195 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors
A Phase 2 study, sponsored by Tulane University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00221195: Completed Phase 2 study, sponsored by Tulane University School of Medicine.
NCT00221195 is a Phase 2 study that has completed, run by Tulane University School of Medicine. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00221195, a Phase 2 study, has completed, sponsored by Tulane University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.
Interventions
- DRUG activated prothrombin complex concentrate (FEIBA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2003-06 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00221195 record still lists
NCT00221195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which activated prothrombin complex concentrate (FEIBA) is the first listed.
NCT00221195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00221195 about?
NCT00221195 is a clinical study titled "Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors". The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.
What is the current status of trial NCT00221195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2003-06. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00221195?
The interventions under investigation include: activated prothrombin complex concentrate (FEIBA) (DRUG).
Who is sponsoring clinical trial NCT00221195?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00221195's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia